Sato Tsuyoshi, Maeta Takahiro, Abe Ryosuke, Yamada Hiroyuki, Ishida Kazuyuki, Yashima-Abo Akiko, Kiyohara Kazuki, Miyajima Shinri, Ito Shigeki
Division of Hematology & Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
Division of Oral and Maxillofacial Surgery, Department of Reconstructive Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University, Yahaba, Japan.
Case Rep Oncol. 2021 Mar 8;14(1):343-346. doi: 10.1159/000512060. eCollection 2021 Jan-Apr.
Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy. A 58-year-old man presented with a right-sided submandibular mass and metastatic lesions in the right supraclavicular and inferior internal jugular nodes. He underwent right submandibulectomy and right neck dissection followed by adjuvant chemoradiotherapy. However, relapse occurred in the hilar lymph node and lumbar spine. Although radiotherapy was performed, a second relapse appeared in the hilar lymph nodes and sacral bone. Immunohistochemical analysis revealed negativity for programmed death ligand-1 (PD-L1) in the primary tumor specimen. The patient then received the anti-programmed death-1 (PD-1) antibody nivolumab. His metastatic lesions were completely eliminated after 48 weeks of therapy. This case reveals that anti-PD-1 antibodies are effective even against PD-L1-negative SDC.
涎腺导管癌（SDC）是一种罕见且侵袭性很强的恶性肿瘤。一名58岁男性患者出现右侧颌下肿块，并伴有右侧锁骨上及颈内静脉下淋巴结转移。他接受了右侧颌下腺切除术及右侧颈部清扫术，随后进行辅助放化疗。然而，肺门淋巴结和腰椎出现复发。尽管再次进行了放疗，但肺门淋巴结和骶骨又出现了二次复发。免疫组化分析显示，原发肿瘤标本中程序性死亡配体-1（PD-L1）呈阴性。该患者随后接受了抗程序性死亡-1（PD-1）抗体纳武单抗治疗。治疗48周后，他的转移病灶完全消除。该病例表明，抗PD-1抗体即使对PD-L1阴性的SDC也有效。
